Squarepoint Ops LLC Boosts Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Squarepoint Ops LLC increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 63.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 119,978 shares of the specialty pharmaceutical company’s stock after acquiring an additional 46,711 shares during the quarter. Squarepoint Ops LLC owned about 0.21% of Supernus Pharmaceuticals worth $3,782,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Invesco Ltd. boosted its position in shares of Supernus Pharmaceuticals by 4.4% in the first quarter. Invesco Ltd. now owns 530,631 shares of the specialty pharmaceutical company’s stock worth $17,378,000 after purchasing an additional 22,562 shares during the period. Nuveen LLC bought a new position in Supernus Pharmaceuticals in the 1st quarter worth $4,393,000. Quantbot Technologies LP purchased a new stake in Supernus Pharmaceuticals in the 1st quarter worth $103,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Supernus Pharmaceuticals during the first quarter valued at about $46,000. Finally, EntryPoint Capital LLC purchased a new position in shares of Supernus Pharmaceuticals in the first quarter valued at about $406,000.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 59,900 shares of the company’s stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the sale, the chief executive officer directly owned 1,206,578 shares in the company, valued at $61,016,649.46. This represents a 4.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders sold 116,235 shares of company stock worth $5,694,447 over the last quarter. Insiders own 8.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SUPN. Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research note on Tuesday, September 30th. TD Cowen lifted their price objective on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Bank of America began coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They set a “buy” rating and a $65.00 target price for the company. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, December 8th. Finally, Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $63.25.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN opened at $48.32 on Wednesday. The company’s fifty day moving average is $48.21 and its 200 day moving average is $42.14. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $57.65. The stock has a market capitalization of $2.77 billion, a PE ratio of -142.11, a P/E/G ratio of 0.57 and a beta of 0.71.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.The business had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $175.82 million. During the same period in the previous year, the business earned $0.69 earnings per share. The business’s quarterly revenue was up 9.3% on a year-over-year basis. As a group, research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.